What are the contraindications of roxadustat?

Contraindications of Roxadustat

Based on the available evidence, roxadustat has no formally established absolute contraindications listed in current guidelines or drug labels. However, the drug carries significant safety concerns that warrant extreme caution or avoidance in specific clinical scenarios.

Key Safety Concerns That Function as Relative Contraindications

Thrombotic Risk - Primary Concern

Roxadustat should be avoided or used with extreme caution in patients at high risk for thrombotic events. The drug demonstrates an increased risk of vascular access thrombosis (VAT) and thromboembolic complications, particularly when hemoglobin rises rapidly 1, 2.

• Pooled analysis shows: Roxadustat increases odds of VAT by 50% (OR: 1.50; 95% CI: 1.06-2.12) 2
• Mechanism: The thrombotic risk appears related to the steeper rate of hemoglobin rise, as identified by FDA safety reviews 1
• Arteriovenous fistula thrombosis: Significantly higher in dialysis patients (7.5% vs. 4.1% with ESA) 1

Clinical implication: Patients with recent thrombotic events, active clotting disorders, or established vascular access should be carefully evaluated before initiating roxadustat.

Acute Liver Failure or Decompensated Cirrhosis

While the FDA drug label evidence provided appears to reference rosuvastatin (a statin) rather than roxadustat 3, emerging case reports document roxadustat-associated cholestatic jaundice in hemodialysis patients 4. Four patients developed cholestatic jaundice with predominant elevations of direct bilirubin and bile acids, with two showing positive rechallenge 4.

Recommendation: Avoid roxadustat in patients with:

• Active liver disease with elevated transaminases
• History of drug-induced cholestasis
• Decompensated cirrhosis

Malignancy - Unresolved Concern

Roxadustat should be used with extreme caution, if at all, in patients with active malignancy or recent cancer history 5. The drug stabilizes HIF-α, which preclinical studies show promotes tumor progression through multiple pathways including metabolic reprogramming, angiogenesis, metastasis, and chemoresistance 5.

• Current renal anemia studies show no increased malignancy risk
• However, observation periods have been too short to adequately assess HIF-driven oncogenic risks
• Tumor progression events were reported as treatment-emergent serious adverse events in chemotherapy-induced anemia studies 5

Clinical approach: Avoid in patients with:

• Active solid tumors or hematologic malignancies
• Cancer history within the past 2-5 years (depending on tumor type and stage)
• Require long-term safety monitoring if use is deemed necessary

Additional High-Risk Scenarios Requiring Avoidance

Cardiovascular Instability

Exercise extreme caution in patients with:

• Recent myocardial infarction or stroke (within 3 months)
• Unstable angina
• Uncontrolled hypertension
• Recent hospitalization for heart failure

The PROTECT trials showed increased MACE risk (HR 1.17; 95% CI 1.01-1.36) in non-dialysis patients, though this was not consistently seen across all HIF-PHI trials 1.

Severe Hyperkalemia Risk

Roxadustat increases hyperkalemia incidence compared to placebo (RR=1.25; 95% CI: 1.02-1.53) 6. Avoid in patients with:

• Baseline potassium >5.5 mEq/L
• Recurrent hyperkalemia episodes
• Concurrent use of multiple potassium-sparing medications

Thyroid Dysfunction

Roxadustat causes reversible central hypothyroidism 7. In hemodialysis patients, TSH decreased from median 2.46 to 1.36 mU/L during treatment, with 5.9% developing extremely low TSH (≤0.1 mU/L) 7.

Avoid or monitor closely in patients with:

• Pre-existing hypothyroidism requiring stable thyroid replacement
• History of thyroid disorders
• Symptoms of hypothyroidism

Practical Clinical Algorithm

DO NOT USE roxadustat if:

1. Active thrombotic event within past 3 months
2. Active malignancy or cancer within past 2 years
3. Acute liver failure or decompensated cirrhosis
4. Recent cardiovascular event (MI, stroke, unstable angina within 3 months)

USE WITH EXTREME CAUTION and close monitoring if:

1. Established vascular access (monitor for thrombosis)
2. History of thrombotic events
3. Baseline hemoglobin <8 g/dL (higher risk of rapid rise)
4. Concurrent anticoagulation needs
5. Thyroid disorders
6. Chronic liver disease

Monitor closely during treatment:

• Hemoglobin weekly initially, then every 2 weeks (avoid rapid rises >1 g/dL per 2 weeks)
• Vascular access patency in dialysis patients
• Potassium levels
• TSH and free T4 at baseline and periodically
• Liver function tests

The evidence consistently shows that the rate of hemoglobin rise is the critical modifiable risk factor for thrombotic complications 1. Dose titration to achieve gradual hemoglobin increases is essential for safety.